Shin Nippon Biomedical Laboratories 미래 성장

Future 기준 확인 3/6

Shin Nippon Biomedical Laboratories (는) 각각 연간 12.3% 및 9.9% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 17.2% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 13.5% 로 예상됩니다.

주요 정보

12.3%

수익 성장률

17.22%

EPS 성장률

Life Sciences 수익 성장	24.0%
매출 성장률	9.9%
향후 자기자본 수익률	13.50%
애널리스트 커버리지	Low
마지막 업데이트	05 Jun 2025

최근 미래 성장 업데이트

Earnings Miss: Shin Nippon Biomedical Laboratories, Ltd. Missed EPS By 88% And Analysts Are Revising Their Forecasts

Aug 09

Shin Nippon Biomedical Laboratories, Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

May 10

Recent updates

Shin Nippon Biomedical Laboratories (TSE:2395) Is Due To Pay A Dividend Of ¥20.00

Jul 09

There May Be Some Bright Spots In Shin Nippon Biomedical Laboratories' (TSE:2395) Earnings

May 15

Investors Continue Waiting On Sidelines For Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395)

Apr 28

Estimating The Intrinsic Value Of Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395)

Apr 04

Shin Nippon Biomedical Laboratories (TSE:2395) Has Affirmed Its Dividend Of ¥30.00

Mar 05

Shin Nippon Biomedical Laboratories (TSE:2395) Is Due To Pay A Dividend Of ¥30.00

Feb 10

Shin Nippon Biomedical Laboratories (TSE:2395) Will Pay A Dividend Of ¥30.00

Jan 10

Shin Nippon Biomedical Laboratories (TSE:2395) Will Pay A Dividend Of ¥30.00

Dec 19

Shin Nippon Biomedical Laboratories (TSE:2395) Is Paying Out A Dividend Of ¥30.00

Dec 02

What Shin Nippon Biomedical Laboratories, Ltd.'s (TSE:2395) 25% Share Price Gain Is Not Telling You

Nov 25

Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00

Sep 19

Earnings Miss: Shin Nippon Biomedical Laboratories, Ltd. Missed EPS By 88% And Analysts Are Revising Their Forecasts

Aug 09

Little Excitement Around Shin Nippon Biomedical Laboratories, Ltd.'s (TSE:2395) Earnings As Shares Take 28% Pounding

Aug 06

Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00

Jul 26

Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00

Jul 12

Shin Nippon Biomedical Laboratories' (TSE:2395) Sluggish Earnings Might Be Just The Beginning Of Its Problems

May 21

Shin Nippon Biomedical Laboratories, Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

May 10

Shin Nippon Biomedical Laboratories (TSE:2395) Is Due To Pay A Dividend Of ¥30.00

Mar 12

Shin Nippon Biomedical Laboratories (TSE:2395) Has Affirmed Its Dividend Of ¥30.00

Feb 27

수익 및 매출 성장 예측

TSE:2395 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (JPY Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
3/31/2028	42,449	6,600	454	5,528	2
3/31/2027	38,613	5,782	764	7,332	2
3/31/2026	34,658	4,573	-4,809	5,848	2
3/31/2025	32,413	4,924	-3,897	7,035	N/A
12/31/2024	30,701	4,942	N/A	N/A	N/A
9/30/2024	27,074	3,896	-11,724	1,650	N/A
6/30/2024	26,195	4,280	N/A	N/A	N/A
3/31/2024	26,450	5,531	-6,498	2,106	N/A
12/31/2023	26,703	5,503	N/A	N/A	N/A
9/30/2023	26,626	4,607	-4,074	1,899	N/A
6/30/2023	26,848	5,489	N/A	N/A	N/A
3/31/2023	25,090	6,060	-950	4,004	N/A
12/31/2022	21,173	6,231	N/A	N/A	N/A
9/30/2022	20,135	8,043	4,382	7,170	N/A
6/30/2022	18,753	7,245	N/A	N/A	N/A
3/31/2022	17,748	7,127	4,339	5,952	N/A
12/31/2021	17,636	7,432	N/A	N/A	N/A
9/30/2021	16,068	6,025	4,075	5,301	N/A
6/30/2021	14,978	4,844	N/A	N/A	N/A
3/31/2021	15,110	3,661	3,629	4,746	N/A
12/31/2020	14,910	2,421	N/A	N/A	N/A
9/30/2020	15,175	2,812	1,389	2,706	N/A
6/30/2020	15,004	3,234	N/A	N/A	N/A
3/31/2020	14,561	2,550	1,788	3,018	N/A
12/31/2019	13,497	1,990	N/A	N/A	N/A
9/30/2019	13,167	1,915	1,784	2,988	N/A
6/30/2019	14,676	1,524	N/A	N/A	N/A
3/31/2019	15,658	1,950	1,794	2,892	N/A
12/31/2018	17,337	-49	N/A	N/A	N/A
9/30/2018	17,928	-993	N/A	2,943	N/A
6/30/2018	16,937	-2,566	N/A	N/A	N/A
3/31/2018	16,600	-3,555	N/A	1,344	N/A
12/31/2017	17,186	-1,072	N/A	N/A	N/A
9/30/2017	17,714	327	N/A	280	N/A
6/30/2017	17,230	260	N/A	N/A	N/A
3/31/2017	17,244	-915	N/A	-849	N/A
12/31/2016	15,880	-1,821	N/A	N/A	N/A
9/30/2016	15,269	-1,273	N/A	-3,109	N/A
6/30/2016	14,922	-1,475	N/A	N/A	N/A
3/31/2016	14,750	2,646	N/A	-3,339	N/A
12/31/2015	15,637	2,060	N/A	N/A	N/A
9/30/2015	16,344	401	N/A	-2,379	N/A
6/30/2015	17,164	1,546	N/A	N/A	N/A
3/31/2015	17,835	-1,385	N/A	-2,156	N/A
12/31/2014	18,058	-417	N/A	N/A	N/A
9/30/2014	17,161	-599	N/A	-1,377	N/A

애널리스트 미래 성장 예측

수입 대 저축률: 2395 의 연간 예상 수익 증가율( 12.3% )이 saving rate( 0.5% 보다 높습니다. ).

수익 vs 시장: 2395 의 연간 수익( 12.3% ) JP 시장( 7.6% 보다 빠르게 성장할 것으로 예상됩니다. 7.6% 연간).

고성장 수익: 2395 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: 2395 의 수익(연간 9.9% ) JP 시장( 4.3% 보다 빠르게 성장할 것으로 예상됩니다. 4.3% 연간).

고성장 수익: 2395 의 수익(연간 9.9% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: 2395 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 13.5 %).

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2025/07/21 01:58
장 마감 주가	2025/07/18 00:00
수익	2025/03/31
연간 수익	2025/03/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처는 미국 증권의 예를 사용했습니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 Github에서 확인할 수 있습니다.

애널리스트 출처

Shin Nippon Biomedical Laboratories, Ltd. 5 애널리스트 중 2 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Yuki Tsukamoto	BofA Global Research
Akitada Iwasa	Daiwa Securities Co. Ltd.
Stephen Barker	Jefferies LLC

Shin Nippon Biomedical Laboratories 미래 성장

Future 기준 확인 3/6

주요 정보

최근 미래 성장 업데이트

Consensus EPS estimates fall by 20%

Consensus EPS estimates increase by 21%

Price target increased by 74% to JP¥2,530

Earnings Miss: Shin Nippon Biomedical Laboratories, Ltd. Missed EPS By 88% And Analysts Are Revising Their Forecasts

Consensus EPS estimates fall by 19%

Shin Nippon Biomedical Laboratories, Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Recent updates

Shin Nippon Biomedical Laboratories (TSE:2395) Is Due To Pay A Dividend Of ¥20.00

Final dividend of JP¥20.00 announced

Shin Nippon Biomedical Laboratories, Ltd. to Report Q1, 2026 Results on Aug 05, 2025

Consensus EPS estimates fall by 20%

There May Be Some Bright Spots In Shin Nippon Biomedical Laboratories' (TSE:2395) Earnings

Now 26% overvalued

New major risk - Share price stability

Full year 2025 earnings: EPS exceeds analyst expectations

Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 27, 2025

Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi™ (Dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine

Investor sentiment improves as stock rises 24%

Investors Continue Waiting On Sidelines For Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395)

Now 27% overvalued

Now 26% overvalued

Investor sentiment deteriorates as stock falls 17%

Estimating The Intrinsic Value Of Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395)

Upcoming dividend of JP¥30.00 per share

Consensus EPS estimates increase by 21%

Shin Nippon Biomedical Laboratories (TSE:2395) Has Affirmed Its Dividend Of ¥30.00

Shin Nippon Biomedical Laboratories, Ltd. to Report Fiscal Year 2025 Results on May 08, 2025

Shin Nippon Biomedical Laboratories (TSE:2395) Is Due To Pay A Dividend Of ¥30.00

Third quarter 2025 earnings released: EPS: JP¥45.01 (vs JP¥19.89 in 3Q 2024)

Shin Nippon Biomedical Laboratories (TSE:2395) Will Pay A Dividend Of ¥30.00

Price target increased by 74% to JP¥2,530

Shin Nippon Biomedical Laboratories (TSE:2395) Will Pay A Dividend Of ¥30.00

Shin Nippon Biomedical Laboratories, Ltd. to Report Q3, 2025 Results on Feb 05, 2025

Shin Nippon Biomedical Laboratories (TSE:2395) Is Paying Out A Dividend Of ¥30.00

First half dividend of JP¥30.00 announced

Satsuma Pharmaceuticals, Inc. and Shin Nippon Biomedical Laboratories, Ltd. Receive FDA Acceptance of NDA Resubmission of STS101 for the Acute Treatment of Migraine with or Without Aura

What Shin Nippon Biomedical Laboratories, Ltd.'s (TSE:2395) 25% Share Price Gain Is Not Telling You

Second quarter 2025 earnings released: EPS: JP¥29.04 (vs JP¥38.27 in 2Q 2024)

New minor risk - Share price stability

Investor sentiment improves as stock rises 19%

Upcoming dividend of JP¥20.00 per share

Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00

Shin Nippon Biomedical Laboratories, Ltd. to Report Q2, 2025 Results on Nov 06, 2024

Earnings Miss: Shin Nippon Biomedical Laboratories, Ltd. Missed EPS By 88% And Analysts Are Revising Their Forecasts

First quarter 2025 earnings: EPS and revenues miss analyst expectations

Little Excitement Around Shin Nippon Biomedical Laboratories, Ltd.'s (TSE:2395) Earnings As Shares Take 28% Pounding

Investor sentiment deteriorates as stock falls 21%

Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00

Shin Nippon Biomedical Laboratories, Ltd. to Report Q1, 2025 Results on Aug 06, 2024

Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00

Final dividend of JP¥20.00 announced

Shin Nippon Biomedical Laboratories' (TSE:2395) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Consensus EPS estimates fall by 19%

Shin Nippon Biomedical Laboratories, Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 24, 2024

Full year 2024 earnings: EPS exceeds analyst expectations

Price target decreased by 13% to JP¥3,150

Upcoming dividend of JP¥30.00 per share

Shin Nippon Biomedical Laboratories (TSE:2395) Is Due To Pay A Dividend Of ¥30.00

Shin Nippon Biomedical Laboratories, Ltd. to Report Fiscal Year 2024 Results on May 08, 2024

Shin Nippon Biomedical Laboratories (TSE:2395) Has Affirmed Its Dividend Of ¥30.00

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 14%

Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024

Shin Nippon Biomedical Laboratories, Ltd. to Report Q3, 2024 Results on Feb 02, 2024

Investor sentiment deteriorates as stock falls 17%

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Shin Nippon Biomedical Laboratories, Ltd. Announces Interim Dividend for the Year Ending 2024, Payable on November 30, 2023; Provides Dividend Guidance for the Year Ending 2024

New minor risk - Share price stability

Upcoming dividend of JP¥20.00 per share at 2.6% yield

Shin Nippon Biomedical Laboratories, Ltd. to Report Q2, 2024 Results on Nov 07, 2023

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Satsuma Pharmaceuticals and Shin Nippon Biomedical Laboratories, Ltd. Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to Be Presented at the American Headache Society's 65th Annual Scientific Meeting

Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395) completed the acquisition of the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. (NasdaqGM:STSA) from a group of sellers.

Price target increased by 15% to JP¥4,150

Consensus EPS estimates fall by 20%, revenue upgraded